Abstract: A method for inducing reprogramming of a cell of a first type which is not a non-hepatocyte (non-hepatocyte cell), into a cell with functional hepatic drug metabolizing and transporting capabilities, is disclosed. The non-hepatocyte is induced to express or overexpress hepatic fate conversion and maturation factors, cultured in somatic cell culture medium, hepatocyte cell culture medium and hepatocyte maturation medium for a sufficient period of time to convert the non-hepatocyte cell into a cell with hepatocyte-like properties. The iHeps induced according to the methods disclosed herein are functional induced hepatocytes (iHeps) in that they express I and II drug-metabolizing enzymes and phase III drug transporters and show superior drug metabolizing activity compared to iHeps obtained by prior art methods. The iHeps thus provide a cell resource for pharmaceutical applications.

Abstract: A method and system provides the ability to detect density of a women's breast by obtaining the concentration of at least one selected biochemical in the breast using a spectrometer, and comparing the concentration obtained with reference measurements which correlate breast density with concentration of the at least one selected biochemical.

Abstract: A method and system for monitoring therapeutic interventions for treating a patient with PTSD comprises using a scanner to obtain pre-treatment neural spectroscopic data of at least one neuromarker chemical in the brain of the patient before treatment, treating the patient with at least one treatment protocol, after treatment, obtaining post-treatment neural spectroscopic data of the at least one neuromarker chemical in the brain of the patient, and comparing the results of the pre-treatment and post-treatment data to enable a determination of the effectiveness of the treatment.

Abstract: A method and system obtains spectral data from the brain of a person undergoing treatment for pain to determine whether the concentration of new chemicals including fucosylated glycans indicates fucosylated glycan concentration levels of a person experiencing pain or returning to normal levels of a healthy person who is not experiencing pain, to assess the person's response to treatment and progress.

Abstract: An integrated MRI and MRS system includes a plurality of different classifiers for detecting the likelihood of the new data to be one of the different diseases/conditions in different body organs, and even the progression of the disease, disease state and condition within that organ.

Abstract: One dimensional (1D) and two dimensional (2D) MR spectroscopy of the brain provides an objective test for pain and level of pain. There are two ways of evaluating the data. The first is conventional analysis of the 2D MRS. The second us the use of data mining methods such as testing for correlation between wavelet-based features and self-reported pain intensity, the MBDA method. Both found multiple spectral regions that were highly correlated with self-reported pain. Two of these spectral regions are consistent with changes to the recently assigned substrate ?-L Fucose and the Fuc-?(1-2) glycans in the human brain. There are common features recorded compared with prior reports using the MBDA method to evaluate pain associated with spinal cord injury and low back pain.

Abstract: A method and system for enabling a practitioner to detect acute stress disorder and PTSD using fMRI comprises looking at functional connectivity dynamics within the visual pathways, limbic, thalamic, paralimbic and prefrontal brain networks observed when individuals are viewing visual images of different facial expressions.

Abstract: The present invention relates to a method and system for using neurochemical markers to enable whether a subject is experiencing acute stress, trauma, or PTSD and providing the capacity to monitor response to therapy on an individual basis. The markers can be an increase of NAA, glutamine or Fuc IV and lactate and a decrease of Fuc IV during the transition from acute stress to PTSD.

Abstract: The present invention relates to an MRS 1D or 2D method and system for obtaining spectral data of the brain of a subject and using neurochemical markers to enable whether a subject is experiencing acute pain, and providing the capacity to monitor response to therapy on an individual basis. The markers can be an increase of Fuc II, III, IV, VII and lactate.

Abstract: A system and method identifies Post Traumatic Stress Disorder by the use of magnetic resonance spectroscopy (MRS) to measure absolute and relative concentrations of metabolites in specific brain regions in the central nervous system or brain. The system and method can be used as a diagnostic tool for the assessment of PTSD. These chemical changes in the brain of those people suffering from PTSD are different from those suffering from head injury, chronic pain and other neurological conditions.

Abstract: The present invention provides an access device for surgery. The access device includes a guide member and a head member. The guide member and head member define a channel configured to receive and guide a sterile flexible scope with a working channel. The guide member and head member cooperate to extend through a small opening of 2 cm or less to access tissue structures. The head member may include surfaces to separate a pericardium from a surface of the heart, stabilize a beating heart and, with the endoscope, provide visibility for the implantation of a therapeutic such as stem cells to the surface of the heart with improved safety and accuracy. Ranges of other diagnostic, application of therapeutics or biologics, and observational applications may be facilitated by the access device, such as TMR, ablation, echo-probe diagnostics, LAA isolation, observation of the same procedures, etc.

Abstract: A replacement heart valve device usable in a medical procedure in relation in heart valve replacement of a patient. In one embodiment, the replacement heart valve device includes a heart valve holder or conduit holder formed in the form of a cylindrical tube having a longitudinal cut substantially extending from one end to the other end of the cylindrical tube, and a conduit formed with a tubular segment of an elastic material. The conduit is mountable onto the heart valve holder or conduit holder or self-expanding stent. In one embodiment, at least a portion of the conduit is formed with a single layer of the elastic material. In another embodiment, at least a portion of the conduit is formed with two layers of the elastic material.

Abstract: A replacement heart valve device usable in a medical procedure in relation in heart valve replacement of a patient. In one embodiment, the replacement heart valve device includes a heart valve holder or conduit holder formed in the form of a cylindrical tube having a longitudinal cut substantially extending from one end to the other end of the cylindrical tube, and a conduit formed with a tubular segment of an elastic material. The conduit is mountable onto the heart valve holder or conduit holder or self-expanding stent. In one embodiment, at least a portion of the conduit is formed with a single layer of the elastic material. In another embodiment, at least a portion of the conduit is formed with two layers of the elastic material.